DAA regimen achieves 91% HCV-1b clearance rate in LT recipients

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • An interferon-free regimen of simeprevir (SMV; Olysio), daclatasvir (DCV; Daklinza), and ribavirin (RBV) achieved a 91% HCV-1b clearance rate in liver transplant (LT) recipients.
  • Coadministration of cyclosporine (CsA) is not recommended.

Why this matters

  • HCV clearance is asso...